|GRANTWAY
EN

Advancing vaccine development for African swine fever

European Comission

Share
Favorite
Feedback
Summary
22 December 2022
12 April 2023
-
-
-
For profit
Individuals
Not for profit (incl. NGOs)
Public sector
R&D and Higher Education
Afghanistan
Albania
Algeria
Angola
Argentina
Armenia
Aruba
Austria
Azerbaijan
Bangladesh
Belarus
Belgium
Belize
Benin
Bhutan
Bolivia
Bonaire
Bosnia and Herzegovina
Botswana
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Cape Verde
Central African Republic
Chad
Colombia
Comoros
Costa Rica
Croatia
Cuba
Curaçao
Cyprus
Czechia
Democratic Republic of the Congo
Denmark
Djibouti
Dominica
Dominican Republic
East Timor
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Eswatini
Ethiopia
Faroe Islands
Fiji
Finland
France
French Polynesia
French Southern and Antarctic Territories
Gabon
Gambia
Georgia
Georgia
Germany
Ghana
Greece
Greenland
Grenada
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Lithuania
Luxembourg
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Mauritania
Mauritius
Micronesia
Moldova
Mongolia
Montenegro
Morocco
Mozambique
Myanmar
Namibia
Nepal
Netherlands
New Caledonia
Nicaragua
Niger
Nigeria
North Korea
North Macedonia
Norway
Pakistan
Palestine
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Poland
Portugal
Republic of Côte d'Ivoire
Republic of the Congo
Romania
Rwanda
Saba
Saint Barthélemy
Saint Lucia
Saint Vincent and the Grenadines
Samoa
Sao Tome and Principe
Senegal
Serbia
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Sudan
Spain
Sri Lanka
St. Eustatius
St. Pierre and Miquelon
Sudan
Suriname
Sweden
Syria
Tajikistan
Tanzania
Thailand
Togo
Tonga
Tunisia
Turkey
Turkmenistan
Tuvalu
Uganda
UK
Ukraine
Uzbekistan
Vanuatu
Venezuela
Vietnam
Wallis and Futuna
Yemen
Zambia
Zimbabwe
Research, Development and Innovation
Overview

ExpectedOutcome :

A successful proposal will support research and innovation to help policy makers and economic operators reduce the burden of African swine fever (ASF), thus contributing to a safeguarding animal health and the economic resilience of the sustainable livestock industry.

Activities under this topic will contribute to the following expected outcomes:

  • Improved capacity to develop ASF pilot vaccines and their companion DIVA tests for the possible prevention and/or eradication of the disease in domestic pigs and wild boars;
  • Vaccination strategies for both wild boar and domestic pigs, addressing different objectives and needs (e.g. eradication in wild boar; emergency or preventive use in domestic pigs).
  • Increased international cooperation on a possible ASF vaccine. Scope :

ASF is a devastating viral disease that has showed its potential for very serious and rapid spread, not only in Europe, but throughout the world. It has a serious socio-economic impact on farming sector and is of major importance in the international trade of animals and animal products. While strict control measures including in particular biosecurity, culling of infected pigs, appropriate management of wild-boar populations, have contributed to reduced spread of the disease, concerns are raised on the possibility to eradicate the disease without vaccination in the long-term.

Global research efforts are starting to show some promising results, but further work on the development of effective and safe ASF vaccines is needed, as an additional tool to re-inforce control and eradication strategies currently in place.

All the following elements should be incorporated:

  • Address the necessary steps for developing pilot vaccines against ASF for domestic pigs and wild boars;
  • Address the necessary steps to develop companion DIVA tests, where feasible.
  • Decipher pathogen genetics/genomics and immune response of the host, to develop innovative approaches to African swine fever vaccine development, at least including those virus types circulating in Europe. Study different types of vaccines and modern techniques to develop novel ASF vaccines;

In order to achieve the expected outcomes, international cooperation is encouraged in particular with North America.

The selected project should take into consideration the EU animal health regulatory framework.

Proposals should ensure adequate involvement of stakeholders from the European Medicines Agency, veterinary authorities, farmers and hunters. Involvement of the pharmaceutical industry is highly recommended.

While it is expected that proposals will present innovative approaches to ASF vaccine development, the projects could consider the relevant activities and outputs of past or ongoing EU funded research, such as VACDIVA[1] and DEFEND[2], and of other international projects on ASF vaccine and build on them where appropriate. They should contribute to the relevant objectives of the Star-Idaz International Consortium[3].

[1] https://vacdiva.eu/

[2] https://defend2020.eu/

[3] https://www.star-idaz.net/

Eligibility

General conditions

  1. Admissibility conditions: described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes

Proposal page limits and layout: described in Part B of the Application Form available in the Submission System

  1. Eligible countries: described in Annex B of the Work Programme General Annexes

A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide .

  1. Other eligibility conditions: described in Annex B of the Work Programme General Annexes

  2. Financial and operational capacity and exclusion: described in Annex C of the Work Programme General Annexes

  3. Evaluation and award:

  • Award criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes

  • Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual

  • Indicative timeline for evaluation and grant agreement: described in Annex F of the Work Programme General Annexes

  1. Legal and financial set-up of the grants: described in Annex G of the Work Programme General Annexes

Specific conditions

  1. Specific conditions: described in the specific topic of the Work Programme

Documents

Call documents:

Standard application form — call-specific application form is available in the Submission System

Standard application form (HE RIA, IA)

Standard evaluation form — will be used with the necessary adaptations

Standard evaluation form (HE RIA, IA)

MGA

HE General MGA v1.0

Additional documents:

HE Main Work Programme 2023–2024 – 1. General Introduction

HE Main Work Programme 2023–2024 – 9. Food, Bioeconomy, Natural Resources, Agriculture and Environment

HE Main Work Programme 2023–2024 – 13. General Annexes

HE Programme Guide

HE Framework Programme and Rules for Participation Regulation 2021/695

HE Specific Programme Decision 2021/764

EU Financial Regulation

Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment

EU Grants AGA — Annotated Model Grant Agreement

Funding & Tenders Portal Online Manual

Funding & Tenders Portal Terms and Conditions

Funding & Tenders Portal Privacy Statement

Learn more or apply
All information about this funding has been collected from and belongs to the funding organization
19 April 2023